Chemotherapy-induced toxic liver injury is a relevant issue in the clinical management of patients affected with metastatic colorectal cancer (mCRC). This retrospective study evaluated patterns of liver toxicity in patients treated with FOLinic acid, Fluorouracil, IRInotecan (FOLFIRI)-based regimens.METHODS:One hundred and fifty-six mCRC patients treated at the University Campus Bio-Medico between January 2003 and January 2013 were included in this retrospective analysis. All patients received a FOLFIRI backbone-based chemotherapy. Basal liver enzymes levels were assessed before starting the treatment and before every therapy course. R ratio and the aspartate aminotransferase/alanine aminotransferase ratio were calculated.RESULTS:Ninety-one patients were male versus 55 female, and the median age of the population was 62 years (range: 38-83). Most patients had liver involvement at the beginning of first-line regimen (101 patients, 64.74%) and 59 patients had received a previous 5-FU based therapy in the adjuvant setting (37.82%). Aspartate aminotransferase level (167.87 vs 41.05 U/l; p < 0.001), Alanine aminotransferase level (94.48 vs 39.80 U/l; p = 0.004) and alkaline phosphatase (289.0 vs 172.44 U/l; p = 0.02) were significantly increased during the first 3 months of treatment. In the entire population, the calculated R ratio was 3.96 (95% CI: 3.25-4.51). In all three regimens, the calculated R ratio was between 2 and 5, without any statistical differences.CONCLUSIONS:FOLFIRI-based hepatotoxicity has been indirectly defined as a mixed pattern injury in all three regimens evaluated.

Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen. A single institution experience / Vincenzi, Bruno; Imperatori, Marco; Picardi, Antonio; VESPASIANI GENTILUCCI, Umberto; Gallo, Paolo; Fausti, Valentina; Spalato Ceruso, Mariella; Santini, Daniele; Tonini, Giuseppe. - In: EXPERT REVIEW OF ANTICANCER THERAPY. - ISSN 1473-7140. - 15:8(2015), pp. 971-976. [10.1586/14737140.2015.1061937]

Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen. A single institution experience

Antonio Picardi;Umberto Vespasiani Gentilucci;Daniele Santini;
2015

Abstract

Chemotherapy-induced toxic liver injury is a relevant issue in the clinical management of patients affected with metastatic colorectal cancer (mCRC). This retrospective study evaluated patterns of liver toxicity in patients treated with FOLinic acid, Fluorouracil, IRInotecan (FOLFIRI)-based regimens.METHODS:One hundred and fifty-six mCRC patients treated at the University Campus Bio-Medico between January 2003 and January 2013 were included in this retrospective analysis. All patients received a FOLFIRI backbone-based chemotherapy. Basal liver enzymes levels were assessed before starting the treatment and before every therapy course. R ratio and the aspartate aminotransferase/alanine aminotransferase ratio were calculated.RESULTS:Ninety-one patients were male versus 55 female, and the median age of the population was 62 years (range: 38-83). Most patients had liver involvement at the beginning of first-line regimen (101 patients, 64.74%) and 59 patients had received a previous 5-FU based therapy in the adjuvant setting (37.82%). Aspartate aminotransferase level (167.87 vs 41.05 U/l; p < 0.001), Alanine aminotransferase level (94.48 vs 39.80 U/l; p = 0.004) and alkaline phosphatase (289.0 vs 172.44 U/l; p = 0.02) were significantly increased during the first 3 months of treatment. In the entire population, the calculated R ratio was 3.96 (95% CI: 3.25-4.51). In all three regimens, the calculated R ratio was between 2 and 5, without any statistical differences.CONCLUSIONS:FOLFIRI-based hepatotoxicity has been indirectly defined as a mixed pattern injury in all three regimens evaluated.
2015
ASTALT ratio; hepatotoxicity; retrospective study
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen. A single institution experience / Vincenzi, Bruno; Imperatori, Marco; Picardi, Antonio; VESPASIANI GENTILUCCI, Umberto; Gallo, Paolo; Fausti, Valentina; Spalato Ceruso, Mariella; Santini, Daniele; Tonini, Giuseppe. - In: EXPERT REVIEW OF ANTICANCER THERAPY. - ISSN 1473-7140. - 15:8(2015), pp. 971-976. [10.1586/14737140.2015.1061937]
File allegati a questo prodotto
File Dimensione Formato  
Vincenzi_Liver-toxicity_2015.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 167.59 kB
Formato Adobe PDF
167.59 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1642222
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact